Wendy Taylor

TL;DR: 6-month trastuzumab treatment is shown to be non-inferior to 12-month treatment in patients with HER2-positive early breast cancer, with less cardiotoxicity and fewer severe adverse events, which support consideration of reduced duration trastzumab for women at similar risk of recurrence as to those included in the trial.

TL;DR: Paclitaxel appears to be a valid alternative taxane backbone to docetaxel, offering similar PFS and ORR with a predictable safety profile and preliminary findings from PERUSE suggest that the safety and efficacy of first-line pertuzumab, trastuzumAB and taxane for HER2-positive LR/MBC are consistent with results from CLEOPATRA.

TL;DR: SafeHer confirms the safety and tolerability of the H SC 600 mg fixed dose for 1 year (every 3 weeks for 18 cycles) as adjuvant therapy with concurrent or sequential chemotherapy for HER2-positive EBC.

TL;DR: The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumabs (CLEOPATRA) trial established the combination of pertuzumaab, trastuzumaba and docetaxel as standard first-line therapy for locally recurrent/metastatic breast cancer (LR/mBC).